Non-Current Liabilities
Total Liabilities
Regeneron Pharmaceuticals Total Liabilities increased by 1.5% to $9.45B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 15.8%, from $8.16B to $9.45B. Over 5 years (FY 2020 to FY 2025), Total Liabilities shows an upward trend with a 8.7% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryLeverage
SignalContext dependent
VolatilityStable
First reportedQ3 2015
Last reportedQ4 2025
How to read this metric
A high level of total liabilities relative to equity indicates a more leveraged capital structure and higher financial risk.
Detailed definition
The aggregate of all current and non-current debts and obligations owed by the company to external parties. It represent...
Peer comparison
Analyzed alongside Total Assets to determine the Debt-to-Asset ratio, which is a standard measure of solvency across all industries.
Metric ID:
total_liabilitiesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.36B | $6.41B | $6.67B | $6.43B | $6.52B | $6.24B | $6.55B | $6.56B | $6.64B | $7.26B | $7.11B | $7.38B | $7.88B | $8.12B | $8.41B | $8.16B | $8.28B | $9.21B | $9.30B | $9.45B |
| QoQ Change | — | +0.9% | +3.9% | -3.5% | +1.3% | -4.3% | +5.0% | +0.2% | +1.1% | +9.3% | -2.1% | +3.8% | +6.8% | +3.0% | +3.6% | -3.0% | +1.5% | +11.2% | +1.0% | +1.5% |
| YoY Change | — | — | — | — | +2.5% | -2.7% | -1.7% | +2.0% | +1.9% | +16.3% | +8.5% | +12.4% | +18.7% | +11.8% | +18.3% | +10.6% | +5.1% | +13.5% | +10.7% | +15.8% |
Range$6.24B – $9.45B
CAGR+8.7%
Avg YoY Growth+9.0%
Median YoY Growth+10.6%
Current Streak4 quarters growth
Total Liabilities at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's total liabilities?
- Regeneron Pharmaceuticals (REGN) reported total liabilities of $9.45B in Q1 2026.
- How has Regeneron Pharmaceuticals's total liabilities changed year-over-year?
- Regeneron Pharmaceuticals's total liabilities increased by 15.8% year-over-year, from $8.16B to $9.45B.
- What is the long-term trend for Regeneron Pharmaceuticals's total liabilities?
- Over 5 years (2020 to 2025), Regeneron Pharmaceuticals's total liabilities has grown at a 8.7% compound annual growth rate (CAGR), from $6.14B to $9.30B.
- What does total liabilities mean?
- The total amount of money the company owes to everyone, both now and in the future.